COVID-19 pandemic and allergen immunotherapy-an EAACI survey
Por:
Pfaar O, Agache I, Bonini M, Brough HA, Chivato T, Del Giacco SR, Gawlik R, Gelincik A, Hoffmann-Sommergruber K, Jutel M, Klimek L, Knol EF, Lauerma A, Ollert M, O'Mahony L, Mortz CG, Palomares O, Riggioni C, Schwarze J, Skypala I, Torres MJ, Untersmayr E, Walusiak-Skorupa J, Chaker A, Giovannini M, Heffler E, Jensen-Jarolim E, Quecchia C, Mónica Paola Sandoval Ruballos, Sahiner U, Tomic Spiric V and Alvaro-Lozano M
Publicada:
1 nov 2021
Ahead of Print:
1 ago 2021
Resumen:
Background As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Methods Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey(R)) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.
Filiaciones:
Pfaar O:
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
Agache I:
Theramed Medical Center, Brasov, Romania
Transylvania University, Brasov, Romania
Bonini M:
National Heart and Lung Institute (NHLI), Imperial College London, London, UK
Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Brough HA:
Paediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK
Children's Allergy Service, Evelina Children's Hospital, Guy's and St, Thomas, Hospital NHS Foundation Trust, London, UK
Chivato T:
School of Medicine, University CEU San Pablo Madrid, Spain
Del Giacco SR:
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
Gawlik R:
Department of Internal Medicine, Allergology, Clinical Immunology, Medical University of Silesia, Katowice, Poland
Gelincik A:
Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Hoffmann-Sommergruber K:
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Jutel M:
ALL-MED Medical Research Institute, Wroclaw, Poland
Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland
Klimek L:
Center for Rhinology and Allergology, Wiesbaden, Germany
Knol EF:
Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
Lauerma A:
Department of Dermatology and Allergology, Helsinki University Hospital Inflammation Centre, University of Helsinki, Helsinki, Finland
Ollert M:
Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark
Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
O'Mahony L:
Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland
Mortz CG:
Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark
Palomares O:
Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Madrid, Spain
:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Schwarze J:
Centre for Inflammation Research and Child Life and Heath, the University of Edinburgh, Edinburgh, UK
Skypala I:
National Heart and Lung Institute (NHLI), Imperial College London, London, UK
Royal Brompton and Harefield NHS Foundation Trust, London, UK
Torres MJ:
Allergy Unit, Malaga Regional University Hospital-UMA-ARADyAL, Málaga, Spain
Untersmayr E:
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Walusiak-Skorupa J:
Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland
Chaker A:
Department of Otolaryngology and Center of Allergy and Environment, TUM School of Medicine, Technical University of Munich, Munich, Germany
Giovannini M:
Allergy Unit, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy
Heffler E:
Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Hospital IRCCS, Rozzano, MI, Italy
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy
Jensen-Jarolim E:
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
The Interuniversity Messerli Research Institute, University of Veterinary Medicine, Vienna, Medical University Vienna, Vienna, Austria
Quecchia C:
"Io e l'Asma" Center, Children's Hospital, ASST Spedali Civili, Brescia, Italy
Mónica Paola Sandoval Ruballos:
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Sahiner U:
Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey
Tomic Spiric V:
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Clinic of Allergology and Immunology, Clinical Centre of Serbia, Belgrade, Serbia
Alvaro-Lozano M:
Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Universitat de Barcelona, Barcelona, Spain
Green Submitted, Green Published, Bronze
|